MS in the Media - 21 December 2018
21 December 2018
- Relapses more likely in people with food allergies
- Reducing Ocrevus injection site reactions
- Fampridine and walking speed
Cell therapy targeting Epstein-Barr virus tested in progressive MS
20 December 2018
This small clinical trial tested the potential of Epstein-Barr virus-specific T cell therapy in secondary and primary progressive MS.
Caring for a loved one with advanced MS
19 December 2018
Living with MS in the family does not only affect the person with MS, but their loved ones as well. In this guest blog, Jen who is a full time carer for her husband Dave, writes about their life living with advanced MS.
MS in the Media - 14 December 2018
14 December 2018
- SMC approves Ocrevus
- Australian stem cell study
- Switching interferons increases relapse risk
Find a cause, find a cure?
13 December 2018
What causes MS? This is something we yet don't know, but there are a lot of theories out there. In this blog guest blogger Emily, takes us through some of them.
Ocrevus (ocrelizumab) approved for relapsing remitting MS in Scotland
10 December 2018
The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as an NHS treatment for relapsing remitting multiple sclerosis in Scotland.
Is there a funny side to MS?
6 December 2018
Is there a funny side to MS? We talk to stand-up comedian Will Berard who has MS, about life with the condition, getting diagnosed and raising awareness through comedy.
Having MS gave Katie the strength to start her own business
6 December 2018
When Katie Silverthorne was diagnosed with MS when she was just 23, she had no idea that her condition would one day spur her on to open her own successful business. In this blog, Katie writes about coming to terms with her MS diagnosis and how it gave her the courage to take...
Abdominal massage for constipation
4 December 2018
This study investigated the use of abdominal massage to ease constipation in people with MS.
MS in the Media - 30 November 2018
30 November 2018
- Depression affected by lifestyle factors
- Gilenya approved for childhood MS
- Lemtrada warning issued
Gilenya licence extended for children and teenagers
29 November 2018
The European Commission has approved the extension of the licence for Gilenya (fingolimod) to include treatment of children and adolescents 10 years or older with relapsing remitting MS.
MS in the Media - 23 November 2018
23 November 2018
- Cognition affects ability to work
- Gender differences in diagnosis
- Rare Gilenya side effect warning
- Fampyra turned down in Scotland